Polyoxidony / Polyoksidoni 12 mg (10 tabs * and similar items

Polyoxidony / Polyoksidoni 12 mg (10 tabs * 12 mg) Pharmacological effect Immunomodulatory drug. The drug increases the body's resistance to bacterial, fungal and viral infections. The basis of the mechanism of the immunomodulatory action of the drug Polyoxidonium is an increase in the ability of leukocytes to phagocytize microorganisms, to stimulate the production of cytokines that activate immunity at initially low levels, to enhance the formation of antibodies to infectious agents. Polyoxidonium activates peripheral blood phagocytes and tissue macrophages, which contributes to more rapid elimination of the pathogen from the body in the presence of focus of infection. In addition, Polyoxidonium activates lymphoid cells located in the regional lymph nodes, namely B cells that produce secretory IgA. When administered sublingually, Polyoxidonium activates lymphoid cells located in the nasal cavity, Eustachian tubes, oropharynx, and bronchi. In addition, Polyoxidonium activates the bactericidal properties of saliva. When administered orally, Polyoxidonium also activates lymphoid cells located in the lymph nodes of the intestine. The consequence of this is an increase in the resistance of the respiratory tract, gastrointestinal tract and ENT organs to infectious agents. and antioxidant activity, has the ability to remove toxins, salts of heavy metals from the body, inhibits lipid peroxidation. These properties are determined by the structure and high-molecular nature of the drug Polyoxidonium. The use of the drug Polyoxidonium against the background of secondary immunodeficiency conditions can increase the effectiveness and reduce the duration of treatment, significantly reduce the use of antibiotics, bronchodilators, corticosteroids, lengthen the remission period. The drug is well tolerated, does not have mitogenic, polyclonal activity, antigenic properties, does not have an allergenic, mutagenic, embryotoxic, teratogenic and carcinogenic effect. Pharmacokinetics Absorption: Polyoxidonium after oral administration is rapidly absorbed from the gastrointestinal tract, bioavailability is approximately 50%. Cmax in plasma is achieved 3 hours after ingestion. The pharmacokinetics of the drug is linear (plasma concentration is proportional to the dose taken). Distribution: Polyoxidonium is a hydrophilic compound. The apparent Vd is approximately 0.5 l / kg, which indicates that the drug is distributed mainly in the interstitial fluid. Half-life 35 min. Does not accumulate. Metabolism and excretion: In the body, it is hydrolyzed to oligomers, which are excreted mainly by the kidneys. T1 / 2 - 18 hours Indications Treatment and prevention of infectious and inflammatory diseases (viral, bacterial and fungal etiology) that are not amenable to standard therapy, both in the acute stage and in remission, in adults and adolescents over 12 years old. As part of complex therapy: - acute and chronic infectious - inflammatory diseases of the oropharynx, paranasal sinuses, upper respiratory tract, inner and middle ear; - allergic diseases complicated by recurrent bacterial, fungal and viral infections (including hay fever, bronchial asthma); - for rehabilitation often and for a long time (more 4-5 times a year) in sick persons. In the form of monotherapy: - prevention of recurrent herpes infection; - seasonal prevention of exacerbations of chronic foci of infections of the oropharynx, paranasal sinuses, upper respiratory tract, inner and middle ear; - in immunocompromised individuals for the prevention of influenza and others acute respiratory infections in the pre-epidemic period; - for the correction of secondary th immunodeficiencies arising from aging or exposure to adverse factors. Contraindications Children under 12 years of age; - increased individual sensitivity to the drug. The drug should be used with caution in acute renal failure, as well as in lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.